South San Francisco, CA, United States of America

Melissa Fleury

This inventor holds 7 USPTO granted patents and 6 published patent applications and 2 EPO patents. Top assignees: Ideaya Biosciences, Inc., Glaxosmithkline Intellectual Property (No.4) Limited, Ideaya Bioscience, Inc.. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Melissa Fleury. Retrieved from https://idiyas.com/inventor/melissa-fleury-ydhnc48q

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 6)

% Patents Active = 71.4

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

6 out of 15

Ideaya Biosciences, Inc.

patents

1 out of 1

Glaxosmithkline Intellectual Property (No.4) Limited

patent

1 out of 1

Ideaya Bioscience, Inc.

patent

where one patent can have more than one assignee

Years Active: 2021-2026

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12766150 - Substituted thiadiazolyl derivatives as DNA polymerase theta inhibitors (2026-10-20),

2. 12662451 - CHEMICAL COMPOUNDS AND USES THEREOF (2026-06-23),

3. 12509454 - Thiadiazolyl derivatives (2025-12-30),

4. 12503467 - 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors (2025-12-23),

5. 11130759 - 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors (2021-09-28),

6. 11084798 - 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors (2021-08-10),

7. 11046691 - 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors (2021-06-29),

Title: The Innovative Contributions of Melissa Fleury

Introduction

Melissa Fleury is a prominent inventor based in South San Francisco, California. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target specific enzymes related to cancer treatment. With a total of three patents to her name, Fleury's work is paving the way for new therapeutic approaches.

Latest Patents

Fleury's latest patents focus on 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A (MAT2A) inhibitors. These compounds are designed to inhibit MAT2A, which plays a crucial role in various cancers, especially those characterized by reduced or absent methylthioadenosine phosphorylase (MTAP) activity. The patents disclose pharmaceutical compositions that comprise these compounds and methods for treating diseases that can be addressed through MAT2A inhibition.

Career Highlights

Throughout her career, Melissa Fleury has worked with notable companies such as Ideaya Biosciences, Inc. and Ideaya Bioscience, Inc. Her innovative research and development efforts have contributed to advancements in cancer treatment methodologies.

Collaborations

Fleury has collaborated with talented individuals in her field, including Muzaffar Alam and Leah Cleary. These partnerships have enhanced her research and expanded the impact of her inventions.

Conclusion

Melissa Fleury's work exemplifies the spirit of innovation in the pharmaceutical industry. Her contributions to cancer treatment through the development of MAT2A inhibitors highlight the importance of targeted therapies in modern medicine.

Profile summary based on public USPTO records.